ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Atrasentan

Also written as “Drug: Atrasentan”, “atrasentan” and “0.25 mg Atrasentan QD”.

Its studies are mostly in Glomerulonephritis, IGA · Prostatic Neoplasms · Renal Insufficiency, Chronic · Kidney Diseases · Diabetic Nephropathies, led by 3 companies.

Drug pageAtrasentan: every studyAll 21 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 10, 200215 company-led studies, 4 open or runningNext primary completion: Apr 14, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott50 open or runningphase 3since May 10, 2002May 10, 2002none ahead
AbbVieits history only50 open or runningphase 3since May 17, 2013Jun 11, 2009none ahead
Novartisits history only54 open or runningphase 3since Sep 12, 2020Sep 12, 2020Apr 14, 2028phase 3 · NCT04573478

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Abbott only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 10, 2002First studies: 2 phase 3 studies in Prostatic NeoplasmsFirst studyNCT00036556, NCT00036543
  2. Jun 3, 2002Phase 2 study in Prostatic NeoplasmsNCT00038662 · 200 enrolled · United States, Canada
  3. Oct 3, 2002Phase 3 study in Prostatic NeoplasmsNCT00046943 · United States
  4. Aug 4, 2005Phase 3 study in Prostatic NeoplasmsNCT00127478 · 166 enrolled · United States, Canada, France and more

TargetBeta

EDNRA →read by rule
“Endothelin receptor ET-A antagonist”ChEMBL 37, by rule

Other programs on EDNRA

ProgramCompanyFurthest phaseStudies
BosentanruleJohnson & Johnsonphase 437
sparsentanruletravere-therapeutics-incphase 49
zibotentanAstraZenecaphase 323
aprocitentanruleIdorsia Pharmaceuticalsphase 314

Studies

All 5 Abbott leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00127478Prostatic Neoplasms · United States, Canada, France and more3Completed166
NCT00046943Prostatic Neoplasms · United States3CompletedJun 2007
NCT00038662Prostatic Neoplasms · United States, Canada2Completed200
NCT00036556Prostatic Neoplasms · United States, Australia, Austria and more3Completed941
NCT00036543Prostatic Neoplasms · United States, Australia, Austria and more3Completed1,000

How it is read

Names in the registry

  • “Atrasentan”, 12 entries
  • “Drug: Atrasentan”, 1 entry
  • “atrasentan”, 1 entry
  • “0.25 mg Atrasentan QD”, 1 entry
  • “0.75 mg Atrasentan QD”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.